Cancer of Liver Clinical Trial
Official title:
Study on Fluid Optimization in Liver Surgery Trough Vigileo/FloTac System Associated to Traditional Monitoring.
Verified date | June 2012 |
Source | Catholic University of the Sacred Heart |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Observational |
The purpose of this study is to analyze hemodynamic changes, in patients undergoing liver resection, through the Vigileo/FloTrac system.
Status | Completed |
Enrollment | 17 |
Est. completion date | May 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 70 Years |
Eligibility |
Inclusion Criteria: - ASA I-III Exclusion Criteria: - Cirrhosis - systolic ventricular contractility or diastolic relaxation alterations - ischemic or valvular diseases - absence of sinusal rhythm - impaired renal function |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Italy | Catholic University of Sacred heart | Rome |
Lead Sponsor | Collaborator |
---|---|
Catholic University of the Sacred Heart |
Italy,
Bein B, Worthmann F, Tonner PH, Paris A, Steinfath M, Hedderich J, Scholz J. Comparison of esophageal Doppler, pulse contour analysis, and real-time pulmonary artery thermodilution for the continuous measurement of cardiac output. J Cardiothorac Vasc Anesth. 2004 Apr;18(2):185-9. — View Citation
Choukèr A, Schachtner T, Schauer R, Dugas M, Löhe F, Martignoni A, Pollwein B, Niklas M, Rau HG, Jauch KW, Peter K, Thiel M. Effects of Pringle manoeuvre and ischaemic preconditioning on haemodynamic stability in patients undergoing elective hepatectomy: a randomized trial. Br J Anaesth. 2004 Aug;93(2):204-11. Epub 2004 Jun 11. — View Citation
Hickey R. How good is arterial pulse contour (LiDCO) and the esophageal Doppler monitor (HemoSonic) in measuring left ventricular stroke volume during venous occlusion? Crit Care Med. 2008 Nov;36(11):3103-4. doi: 10.1097/CCM.0b013e31818b927a. — View Citation
Marquez J, McCurry K, Severyn DA, Pinsky MR. Ability of pulse power, esophageal Doppler, and arterial pulse pressure to estimate rapid changes in stroke volume in humans. Crit Care Med. 2008 Nov;36(11):3001-7. doi: 10.1097/CCM.0b013e31818b31f0. — View Citation
Mayer J, Boldt J, Mengistu AM, Röhm KD, Suttner S. Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: a randomized, controlled trial. Crit Care. 2010;14(1):R18. doi: 10.1186/cc8875. Epub 2010 Feb 15. — View Citation
Smyrniotis V, Kostopanagiotou G, Theodoraki K, Tsantoulas D, Contis JC. The role of central venous pressure and type of vascular control in blood loss during major liver resections. Am J Surg. 2004 Mar;187(3):398-402. — View Citation
Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg. 1988 Dec;208(6):679-87. — View Citation
Torzilli G, Makuuchi M, Inoue K. The vascular control in liver resection: revisitation of a controversial issue. Hepatogastroenterology. 2002 Jan-Feb;49(43):28-31. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Stroke volume variation | Evaluation of changes in Stroke Volume Variation from Vigileo/FloTrac system during liver resection. | at time of surgery | Yes |
Secondary | Stroke volume variation | Evaluation of changes in Stroke Volume Variation at the end of liver resection, during fluid optimization. | at the end of surgery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05109052 -
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Completed |
NCT05030090 -
Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer
|
N/A | |
Terminated |
NCT00669136 -
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT05041335 -
Wet Heparinized Suction for Abdominal Cancer
|
N/A | |
Recruiting |
NCT04258813 -
Onco-primary Care Networking to Support TEAM-based Care
|
N/A | |
Completed |
NCT03299036 -
Drug-loadable(T-ACE Beads)for Hepatoma Embolization Therapy
|
N/A | |
Recruiting |
NCT03323996 -
Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients
|
N/A | |
Not yet recruiting |
NCT06458998 -
Getting To Implementation: Improving Cancer Screening for Veterans
|
N/A | |
Completed |
NCT02044224 -
Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
|
Phase 4 | |
Not yet recruiting |
NCT03607643 -
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT05643833 -
Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma
|
||
Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
Not yet recruiting |
NCT03766776 -
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
|
N/A | |
Completed |
NCT02016391 -
Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
|
Phase 4 | |
Recruiting |
NCT00730860 -
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
|
N/A | |
Terminated |
NCT00216437 -
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT04172714 -
Low-dose Y90 Treatment Planning for HCC
|
N/A | |
Active, not recruiting |
NCT03347162 -
Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
|